Sun Sep 07 09:17:48 UTC 2025: **Summary:**

Researchers have found that alternating between two chemotherapy schedules, the maximum tolerated dose (MTD) and the low-dose metronomic (LDM), can be more effective in controlling cancer than using either schedule alone. This strategy leverages Parrondo’s paradox, where combining two losing strategies can result in a winning one, by delaying the rise of resistant cancer cells and preserving healthy cells longer. The findings, based on mathematical models and computer simulations, need to be tested in real-world settings.

**News Article:**

**Alternating Chemotherapy Schedules Shows Promise in Cancer Control: Study Explores Parrondo’s Paradox**

**New Delhi, India – September 7, 2025** – In a potentially groundbreaking development for cancer treatment, a new study published in *Physical Review E* suggests that alternating between different chemotherapy schedules could significantly improve treatment outcomes. Researchers have found that strategically switching between the maximum tolerated dose (MTD) and low-dose metronomic (LDM) schedules may delay the rise of resistant cancer cells and preserve healthy cells longer than using either method alone.

The concept is based on Parrondo’s paradox, a counterintuitive phenomenon from game theory and physics. Parrondo’s paradox demonstrates that two losing strategies, when combined in a specific sequence, can result in a winning strategy. The study shows that MTD delivers high doses of drugs at spaced intervals and tends to leave behind resistant cancer cells that eventually take over. On the other hand LDM delivers smaller, continuous doses but has the possibility of sensitive cells escaping control, and if it is too strong, resistant cells dominate.

Using mathematical models and computer simulations, researchers found that cycling between these two schedules could achieve a more effective long-term control. This is a weak form of Parrondo’s paradox.

“This approach essentially achieves what neither individual chemotherapy schedule can accomplish on its own,” explained a lead researcher involved in the study. “By strategically alternating between MTD and LDM, we can potentially delay the development of resistance and improve the overall effectiveness of treatment.”

While the findings are promising, researchers emphasize that this strategy still needs to be tested in real-world clinical trials. If proven successful, this approach could represent a significant advancement in cancer therapy, offering hope for more effective and durable treatment outcomes.

Read More